Red Leaf with EVE Health Group CSO & Executive Director Dr Stuart Gunzburg

Welcome to the Red Leaf Securities podcast.Today we’re joined by Dr Stuart Gunzburg, CSO and Executive Director of EVE Health Group. Stuart sits at the intersection of science, clinical development, and capital markets, helping guide EVE’s strategy as it targets large, patent-expiry pharmaceutical markets through reformulated therapies and telehealth-enabled distribution.In this conversation, we explore the science and commercial pathway behind EVE’s lead products Libbo® and Dyspro™, the realities of clinical adoption in a competitive prescribing environment, and the regulatory and execution risks that matter most. We also unpack how telehealth is reshaping the route-to-market, and what needs to occur for EVE to transition from early-stage development into meaningful commercial scale.Let’s get into it.Become a supporter of this podcast: https://www.spreaker.com/podcast/red-leaf-securities--6387900/support.